Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 6/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | PLAT | P00750 | 1/20 | 0.47 |
| ▸ | KLK1 | P06870 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9741360 | 0.98 | PRSS1 (0.59) | LMNAMAPK1HTTRAB9APRSS1 | |
| Hydrochloric Acid SCHEMBL9815151 | 0.96 | LMNA (0.57) | LMNAMAPK1HTTRAB9APRSS1 | |
| SCHEMBL10143507 | 0.85 | PRSS1 (0.58) | LMNAMAPK1HTTRAB9APRSS1 | |
| SCHEMBL3368852 | 0.84 | PRSS1 (0.77) | MAPK1PRSS1PRSS2PRSS3PLAU | |
| Hydrochloric Acid SCHEMBL5112303 | 0.84 | PRSS1 (0.59) | LMNAPRSS1PRSS2PRSS3PLAU | |
| Hydrochloric Acid SCHEMBL6287246 | 0.82 | PRSS1 (0.77) | PRSS1PRSS2PRSS3PLAU | |
| SCHEMBL30278904 | 0.81 | HTT (0.71) | LMNAMAPK1HTTRAB9AAR | |
| SCHEMBL3668139 | 0.81 | HTT (0.61) | LMNAMAPK1HTTRAB9APDE4A | |
| SCHEMBL1477740 | 0.81 | HTT (0.71) | LMNAMAPK1HTTRAB9AAR | |
| SCHEMBL20936840 | 0.80 | LMNA (0.51) | LMNAMAPK1HTTRAB9APRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030565-B1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-9688683-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-3030565-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-06-15 | — | — | EP | disclosed |
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-06-02 | — | — | US | disclosed |
| WO-2015018534-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2015-02-12 | — | — | WO | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| EP-0339252-A2 | 2,5-disubstituted pyrazine derivatives, pyrimidine derivatives, and liquid crystal containing the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | PDE4A, PDE4B, TYMP | LMNA 2843/4885MAPK1 2807/4885HTT 4407/4885 |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | LMNA 3998/4885MAPK1 1216/4885HTT 4191/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | LMNA 3998/4885MAPK1 1216/4885HTT 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.